Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer
Completed
Orion Corporation, Orion Pharma
Phase 3
2014-09-12
The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in
patients with non-metastatic castration-resistant prostate cancer.
Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer
Completed
Bayer
Phase 3
2014-09-12
The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in
patients with non-metastatic castration-resistant prostate cancer.
ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
Active, not recruiting
Orion Corporation, Orion Pharma
Phase 3
2016-11-30
The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide
(ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in
patients with metastatic hormone sensitive prostate cancer.
ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
Active, not recruiting
Bayer
Phase 3
2016-11-30
The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide
(ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in
patients with metastatic hormone sensitive prostate cancer.
A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide
Completed
Bayer
Early Phase 1
2017-09-05
The purpose of this study is to evaluate the effect of short-term treatment with darolutamide
on breast cancer cells (i.e., how the treatment may change the genes or proteins in breast
cancer cells) and to evaluate its safety and the way it is tolerated by subjects.
The intent is to study these changes in order to have a better understanding of the potential
use of darolutamide for women with EBC, know which patients are likely or unlikely to respond
to this treatment, and determine how darolutamide may be combined with other anti-cancer
drugs.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
